DV
Dividend Vision

RGC — Regencell Bioscience Holdings Ltd

Regencell Bioscience Holdings Ltd (RGC)

Total return is 1872.5% over the past 5.1 years, 1779.9 points ahead of SPY at 92.6%. Its deepest 1-year drawdown was 91.0%.

Regencell Bioscience Holdings Limited is a Traditional Chinese medicine bioscience company focused on researching, developing, and commercializing TCM treatments for neurocognitive disorders, particularly attention deficit hyperactivity disorder and autism spectrum disorder. The company does not currently distribute dividends or other income to shareholders. This security appeals primarily to growth-oriented investors interested in the biotech and alternative medicine sectors rather than those seeking current income.

RGC key facts

Asset type
Stock
Asset class
Equity
Inception date
07/16/2021
Last close
$5.45
Market cap
$2,996,602,624
Average volume
132200.0
Beta
1.828
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.01